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People with Down syndrome (DS) are at high risk for developing Alzheimer disease
(AD). Neuropathology consistent with AD is present by 40 years of age and dementia
may develop up to a decade later. In this review, we describe metabolic and vascular
neuroimaging studies in DS that suggest these functional changes are a key feature of
aging, linked to cognitive decline and AD in this vulnerable cohort. FDG-PET imaging
in DS suggests systematic reductions in glucose metabolism in posterior cingulate
and parietotemporal cortex. Magentic resonance spectroscopy studies show consistent
decreases in neuronal health and increased myoinositol, suggesting inflammation. There
are few vascular imaging studies in DS suggesting a gap in our knowledge. Future studies
would benefit from longitudinal measures and combining various imaging approaches to
identify early signs of dementia in DS that may be amenable to intervention.
Keywords: dementia, FDG-PET, hypometabolism, hypermetabolism, myoinositol, MR spectroscopy, T2∗,
trisomy 21
INTRODUCTION
The life expectancy of people with Down syndrome (DS) continues to increase due to improved
health care and management of co-occurring illnesses (Bittles and Glasson, 2004). Consequently
there are more people with DS and the population has grown from 49,923 in 1950 to 206,
336 in 2010 (de Graaf et al., 2017). However, mortality rate is higher in people with DS in
older ages relative to the general population (Ng et al., 2017) and further, some deaths such
as those due to respiratory disorders and epilepsy may be amenable to medical intervention
(Hosking et al., 2016). As with the general population, the risk of developing health-related
problems increases as people with DS get older. In particular, people with DS are at a high
risk of developing cognitive impairment and clinical dementia after the age of 50 years (Zigman
et al., 1996; Sinai et al., 2018). Virtually all adults with DS develop the neuropathology for
a brain-based Alzheimer disease (AD) diagnosis by the age of 40 years (reviewed in Head
et al., 2016). This is thought to be due to the lifelong overexpression of the APP gene on
chromosome 21 leading to early onset and rapid accumulation of beta-amyloid (Aβ) with age
(Head et al., 2016). Thus, by studying individuals with DS across the lifespan it is possible
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to identify early biomarkers of AD pathogenesis that may not
be feasible in the general population as the age of onset of
AD varies tremendously (e.g., 50-over 100 years). As will be
discussed later in this review, cerebrovascular pathology may
help to accelerate AD in DS and be an important contributor to
dementia. Interestingly, a subset of adults with DS never develops
dementia even in the presence of this AD pathology (Franceschi
et al., 1990; Schupf and Sergievsky, 2002; Head et al., 2012a,b).
Neuroimaging studies help us detect structural, connectivity,
activity, neurochemical, and vascular/metabolic functional
changes with age and with the development of AD. As the
development of AD neuropathology in DS is strongly age-
dependent, we can learn about early changes associated with the
progression of AD through neuroimaging studies in DS (Neale
et al., 2018). These studies not only help us understand aging and
AD in people with DS but can translate to our understanding of
AD in the general population. For example, Jack and Holtzman
(2013) proposed a hypothetical series of biomarker events
including neuroimaging outcomes that may occur prior to
changes in cognition and be predictive of decline in the general
population. For example, Jack and colleagues suggest that Aβ
can be detected prior to brain structure changes, which in turn
are detectable prior to mild cognitive impairment and dementia.
A similar series of biomarker events can be hypothetically
applied for people with DS but using age as opposed to the
clinical disease stage as the time axis. Whereas in the general
population, biomarker changes reflecting progressive AD are
plotted as a function of the cognitive continiuum, in DS we can
use age as a representative to AD pathogenesis. It is clear from
this hypothetical model that neuroimaging can provide early
markers of dementia-associated brain changes and the inclusion
of vascular or metabolic imaging may play an important role by
providing even earlier information regarding AD pathogenesis.
METABOLIC IMAGING
BIOMARKERS—FDG-PET
Metabolic imaging using positron emission tomography (PET)
has consistently shown reductions in glucose utilization in
vulnerable brain regions in sporadic AD (Silverman and Phelps,
2001). In particular, the precuneus, posterior cingulate cortex
and posterior parietotemporal lobes may be the earliest site
of reduced glucose metabolism (FDG-PET) prior to onset of
symptoms (Minoshima et al., 1997). In AD, the extent of cerebral
metabolic rate of glucose from FDG-PET studies (CMRglu) is
correlated with the severity of dementia (Minoshima et al., 1997).
As AD progresses, more brain regions show declines in CMRglu
such as the frontal cortex. CMRglu from FDG-PET can also
predict AD neuropathology with 84–93% sensitivity and 73%
specificity (Silverman et al., 2001; Jagust et al., 2007).
There are relatively few FDG-PET studies in DS with the
majority being acquired under resting conditions (Table 1
summarizes studies since 1983). However the results of
these studies have been relatively consistent. First, younger
individuals with DS (without dementia) show increased
glucose metabolism (Schwartz et al., 1983; Cutler, 1986;
Azari et al., 1994a; Haier et al., 2003, 2008; Lengyel et al.,
2006; Matthews et al., 2016) relative to age matched controls
in all but one study (Schapiro et al., 1992b). The regions
that show hypermetabolism include the prefrontal cortex,
sensorimotor cortex, thalamus, inferior temporal/entorhinal
cortex. Interestingly, increased glucose metabolic rate is
associated with decreased gray matter volume in the temporal
cortex including the parahippocampus/hippocampus suggesting
that hypermetabolism is a compensatory response (Haier et al.,
2008). Indeed, autopsy studies of the same brain region in a case
series of DS shows evidence of neuronal sprouting positive for
tau phosphorylation suggesting a mechanistic basis for increased
glucose metabolism in middle age (Head et al., 2003). Other
molecular events may also underlie this phenomenon (reviewed
in Head et al., 2007).
In contrast, older individuals with DS and particularly
those with dementia show hypometabolism in multiple studies
(Schwartz et al., 1983; Cutler, 1986; Schapiro et al., 1992a; Azari
et al., 1994a,b; Rafii et al., 2015; Sabbagh et al., 2015; Matthews
et al., 2016). Brain regions that appear to be systematically
affected under either resting or active conditions include the
posterior cingulate cortex, hippocampus, parietal and temporal
cortex consistent with reports in sporadic AD (Minoshima et al.,
1997; Pietrini et al., 1997; Silverman and Phelps, 2001). Further,
in a 45 year old female with mosaic/translation DS with clinical
signs of early dementia, a pattern of hypometabolism similar to
that of sporadic AD was observed (Schapiro et al., 1992a).
Reduced glucose metabolism in older adults with DS
and dementia is associated with decreased cortical volumes
(Matthews et al., 2016), increased amyloid binding with
florbetapir (Matthews et al., 2016) and increased tau binding
using AV-1451 (Rafii et al., 2017). Some studies report
associations between cognition and glucose metabolism (Haier
et al., 2008; Sabbagh et al., 2015; Matthews et al., 2016) but not
all (Rafii et al., 2015), with variable results likely due to smaller
sample sizes. In one of the only longitudinal studies that was
found, Dani and colleagues reported stable glucose metabolic
rates over a 7 year period of time unless clinical dementia had
evolved (occurred in one person with DS) leading to rapid
glucose metabolic decline in parietal and temporal cortices (Dani
et al., 1996).
Reductions in glucose metabolism may lead to or reflect
neuronal loss, synapse loss, and/or mitochondrial dysfunction.
Given that all these events are thought to occur with age and
dementia in DS (Head et al., 2016), PET imaging can provide
useful information with respect to brain function but there is a
clear need for more longitudinal studies that includes measures
of cognition. It is also notable that despite the posterior cingulate
cortex being an early site of glucose metabolic losses, there
are few studies of AD neuropathology in this region in DS.
The use of FDG-PET to capture information about metabolism
requires the use of intravenous injections of radioactive ligands.
This procedure may be problematic for some participants, their
families and particularly for those with dementia. However, as an
outcome measure that may reflect a rapid response to treatment
that is targeting metabolism, FDG-PET has utility. In future,
similar outcomes reflectingmetabolic changes such as blood flow,
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TABLE 1 | Summary of FDG-PET studies in DS (since 1983).
Authors Date Resting
or active
Cohort Clinical data Outcome References
Schwartz
et al.
1983 Resting n = 4 young DS 19–27 years and
n = 1 aged DS 51 years, n = 10
young controls 21–33 years and
n = 8 aged controls 45–55 years
None Increased glucose metabolic rate in
multiple brain regions in young DS
relative to age matched controls
whereas the 51 year old showed
reduced metabolic rate to young DS
controls (but not to old controls).
Schwartz
et al., 1983
Cutler 1986 Resting n = 10 DS 19–23 years, n = 4
DS 41–64 year (2 were
demented) and n = 14 young
20–35 year and 19 40–60 year
None Young and old control groups not
different. CMRglu higher by 20–30%
in young DS compared to young
controls, lower CMRglu in old DS
compared to young DS but not
different from controls.
Cutler, 1986
Schapiro
et al.
1988 Resting n = 1 DS 47 years with autopsy
confirmed AD, n = 13
non-demented DS, 19–33 years)
General intelligence,
visuospatial ability,
language and memory
Glucose metabolism was 28% less in
the demented DS case involving the
parietal and temporal cortex.
Schapiro
et al., 1988
Schapiro
et al.
1990 Resting n = 14 non-demented DS 25–38
years, n = 13 controls 22–38
years.
PPVT No differences in glucose metabolism
in non-demented adults with DS
relative to controls.
Schapiro
et al., 1990
Horwitz et al. 1990 Resting n = 14 DS < 34 years vs. n = 24
controls
None The correlation between regional
rates of glucose metabolism in DS
was large and negative for the inferior
frontal gyrus including Broca’s area
whereas in controls this association
was positive.
Horwitz et al.,
1990
Schapiro
et al.
1992 Resting n = 20 DS 19–34 years and 9
older DS, 45–63 years. Controls
were n = 13 22 = 39 years.
Stanford-Binet, PPVT,
Digit Span, Block
Tapping Span and
Object Pointing Span,
Memory for Object
subtest from DSMSE
and recognition
memory for designs,
grammatic closure and
manual expression,
Hiskey Nebraska Block
Pattery Subtest,
WISC-R Block design
No difference in glucose metabolism
found between young DS and young
controls. DS with dementia had
hypometabolism in association
cortices (parietal and lateral temporal)
and primary neocortex (sensorimotor
and occipital). Mosaic/translation
person with DS (45 years) with mild
dementia showed reduced temporal
glucose metabolism.
Schapiro
et al., 1992a
Azari et al. 1994 Resting n = 14 DS 26–38 years vs. n-17
controls
Stanford-Binet, DSMSE DS vs. CTL not different on whole
brain CMRglu, DS<CTL in left
paracentral, left inferior parietal,
anterior cingulate, posterior cingulate,
right cerebellum, left cerebellum,
DS>CTL left prefrontal, right
sensorimotor, right thalamus.
Azari et al.,
1994b
Azari et al. 1994 Resting n = 15 Young DS, n = 10 older
DS without dementia, n = 4 DS
with dementia and n = 15 young
controls
Stanford-Binet, DSMSE All DS with dementia and some of the
DS without dementia scans appeared
similar to that of AD patterns.
Azari et al.,
1994a
Dani et al. 1996 Resting n = 12 non-demented DS 31–59
years, longitudinal evaluation—n
= 2 (49,50 years) became
demented
DSMSE People with DS who were
non-demented did not show changes
in glucose metabolism over 7 years.
Two people developed dementia after
7 years and showed a rapid decline in
glucose metabolism in parietal and
temporal regions.
Dani et al.,
1996
Pietrini et al. 1997 Resting
and
audiovisual
stimulation
n = 8 DS 32–38 years and n = 8
DS 43–61 years
Stanford-Binet
Intelligence Scale,
DSMSE, PPVT
At rest, no differences in glucose
metabolism were observed. During
stimulation, older subjects with DS
showed reduced glucose metabolic
rates in parietal and temporal cortex.
Pietrini et al.,
1997
(Continued)
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TABLE 1 | Continued
Authors Date Resting
or active
Cohort Clinical data Outcome References
Haier et al. 2003 Continuous
performance
task
n = 17 DS (non-demented
34–55 years), n- n = 10
moderate AD, n = 12 young
controls, n = 12 old controls)
Wechsler Adult
Intelligence Scale III,
DSDS, DMR, MMSE
(for AD)
DS and AD participants had lower
glucose metabolic rates relative to
each of their control groups in the
posterior cingulate. DS had higher
GMR in inferior temporal/entorhinal
cortex where AD subjects had lower
GMR. Non-demented people with DS
showed hypermetabolism as a
compensatory response.
Haier et al.,
2003
Lengyel et al. 2006 Resting n = 11 DS (5–24 years) and n =
9 control (4–24 years)
None Glucose metabolic rate was higher in
DS relative to controls in 6 regions:
left medial temporal gyrus, left
precentral and inferior frontal gyri,
anterior cingulate gyri.
Lengyel et al.,
2006
Haier et al. 2008 Continuous
performance
task
n = 19 non-demented DS 34–52
years
DMR Higher glucose metabolic rate was
associated with decreased gray
matter volume in temporal cortex
including the
parahippocampus/hippocampus, in
the thalamus, caudate, and frontal
lobe. Results consistent with a
compensatory response.
Haier et al.,
2008
Rafii et al. 2015 Resting n = 12 non-demented DS
(30–60 years)
CANTAB, RBANS,
VABS, Observer
Memory
Questionnaire-Parent
Form, Anxiety
Depression and Mood
Scale, Cambridge
Examination for Mental
Disorders of Older
People with Down’s
syndrome and other
with Intellectual
Disability, Dalton
Dyspraxia scale,
Goodenough-Harris
Draw-A-Person Test
People with DS over 39 years age of
showed consistent hypometabolism
by clinical read. No correlations with
cognition.
Rafii et al.,
2015
Sabbagh
et al.
2015 Resting n = 5 DS with AD, 12
non-demented DS and 9 normal
controls
DMR, MMSE, BPT, SIB
and VABS
DS with AD showed hypometabolism
in posterior cingulate, lateral parietal,
and temporal and frontal regions.
Non-demented and demented DS
had lower glucose metabolic rates in
additional frontal regions compared
with controls.
Sabbagh
et al., 2015
Matthews
et al.
2016 n = 12 non-demented DS
(32–61 years), n = 12 normal, n
= 12 early MCI, n = 12 late MCI,
n = 12 AD and n = 12 and
controls from ADNI
VABS Posterior cingulate cortex and
hippocampus showed
hypometabolism in DS relative to
controls. Lower glucose metabolic
rate was observed in regions showing
volumetric losses (mid cingulate,
anterior cingulate, paracentral lobule,
and hippocampus). Hypermetabolism
was observed with preserved volume
in the prefrontal cortex but reduced
volume in occipital cortex. Patterns of
glucose metabolism and volume
losses corresponded to amyloid
burden (florbetapir) and cognition.
Matthews
et al., 2016
(Continued)
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TABLE 1 | Continued
Authors Date Resting
or active
Cohort Clinical data Outcome References
Rafii et al. 2017 Resting n = 12 non-demented DS 30–60
years, n = 12 normal older
adults, n = 12 AD
CANTAB, RBANS,
VABS, Observer
Memory
Questionnaire-Parent
Form, Anxiety
Depression and Mood
Scale, Cambridge
Examination for Mental
Disorders of Older
People with Down’s
syndrome and other
with Intellectual
Disability, Dalton
Dyspraxia scale,
Goodenough-Harris
Draw-A-Person Test
Areas with lower glucose metabolic
rates were associated with tau
accumulation by PET (F-AV-1451).
Rafii et al.,
2017
Lao et al. 2018 Resting n = 16 non-demented DS (Avg
age 35 years—PiB negative), n =
5 non-demented DS (Avg age 47
years—PiB positive), n = 3
demented DS (Avg age 49 years)
PPVT Glucose metabolism was reduced in
the parietal cortex with increased PiB
(amyloid) binding. Glucose
metabolism was negatively
associated with age (frontal, parietal,
and temporal cortex). No correlation
between striatal binding for PiB
(amyloid) and glucose metabolism.
Lao et al.,
2018
CMRglu, glucose cerebral metabolic rate; GMR, glucose metabolic rate; PPVT, Peabody Picture Vocabulary Test; DSMSE, Down syndrome mental state examination; WISC, Wechsler
Intelligence Scale for Children; DSDS, Dementia scale for Down syndrome; DMR, dementia questionnaire for mentally retarded persons; RBANS, Repeatable Battery for the Assessment
of Neuropsychological status; CANTAB, Cambridge Neuropsychological Test Automated Battery; VABS, Vineland Adaptive Behavior Scale; BPT, Brief Praxis Test; SIB, severe impairment
battery.
may be obtainable using relatively short MR protocols such as
arterial spin labeling (7min). Further, as will be discussed next,
magnetic resonance spectroscopy, which is also a relatively short
protocol (5min) that may be useful for a broader spectrum of
participants can provide specific metabolic markers that could
help dissect the different neuronal/glial pathways that signal
onset of dementia.
METABOLIC IMAGING
BIOMARKERS—MRS
Proton magnetic resonance spectroscopy (1H-MRS) has been
widely used to characterize the neurochemistry of brain
health and disease. In particular, the neuronal markers of N-
acetylaspartate (NAA) and glutamate-glutamine complex (Glx)
decrease, and the glial marker of myo-inositol (MI) increases,
both correlate with clinical variables in aging and AD (Parnetti
et al., 1997; Lin and Rothman, 2014). It is thought that
lower levels of NAA or Glx reflects neuronal loss or injury;
neuroinflammation is associated with activated astrocytes and
microglial cells leading to increased MI (Chang et al., 2013). The
ratio of NAA toMI can also be used to distinguish non-demented
from demented people (cf. Lin et al., 2005).
In DS, there have been several studies using MRS with
assessments done for posterior cingulate cortex, hippocampus,
frontal cortex, occipital cortex, and parietal cortex with
comparisons to age matched controls (Table 2). Decreased NAA
and increasedMI is observed relatively consistently across studies
in non-demented adults with DS compared with age matched
non-DS controls (Shonk and Ross, 1995; Berry et al., 1999; Huang
et al., 1999; Beacher et al., 2005; Lamar et al., 2011; Lin et al., 2016)
with a few exceptions (Murata et al., 1993; Smigielska-Kuzia et al.,
2010). Hippocampal Glx was not different in people withDS from
controls (Tan et al., 2014). It may not be surprising that MI levels
are generally higher in people with DS as the MI cotransporter
(SLC5A3) gene is on chromosome 21 and is overexpressed in
DS (Berry et al., 1995). Further, synaptojanin 1 (gene also on
chromosome 21) can lead to increased gliosis (Herrera et al.,
2009) and thus possibly, higher MI levels.
With age, older people with DS show higher MI and lower
NAA than younger people with DS.MI was higher in the occipital
and parietal cortex of older DS subjects relative to younger people
with DS (Huang et al., 1999). In the hippocampus of older adults
with dementia with DS, MI is also higher and NAA lower when
compared to non-demented people with DS (Lamar et al., 2011)
but Glx is unchanged (Tan et al., 2014). In the posterior cingulate
cortex, MI was not significantly different in people with DS who
were demented compared with those who were not demented,
but NAA was significantly decreased (Lin et al., 2016). However,
there is a case report of an individual with DS who was demented
showing higher MI and lower NAA relative to non-demented
DS individuals (Shonk and Ross, 1995). Further increases in MI
reported in some studies with aging and dementia may reflect
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TABLE 2 | Summary of MRS studies in DS (since 1993).
Authors Date Brain Region Cohort Clinical data Outcome References
Murata et al. 1993 white matter
around the
anterior horn of
the lateral ventricle
of frontal cortex
n = 18 DS 20–40 years, n
= 15 controls (avg age 35.8
years)
Koh’s
Block-Design Test,
Goodenough’s
Draw a Man Test
No differences in NAA noted across
the groups nor as a function of age.
MI was not analyzed. Note, many of
these DS participants were
institutionalized and controls were
physicians and staff members. Two
people with DS were mosaic.
Murata et al., 1993
Shonk & Ross 1995 N/A n = 23 non-demented DS
(age unknown), n = 1
demented DS (age
unknown)
Unknown MI was elevated in non-demented
people with DS relative to controls
and further elevated in DS with
dementia. NAA was decreased in the
DS with dementia participant.
Shonk and Ross,
1995
Huang et al. 1999 parietal and
occipital cortex
n = 8 young DS 28–39
years, n-11 non-demented
older DS 42–62 years, n =
8 young controls 22–39
years and n = 9 old controls
40–64 years
None MI was 50% higher in occipital and
parietal cortex of adults with DS
relative to controls. Older DS subjects
had higher MI than younger DS
subjects. NAA was lower in older DS
and controls relative to younger
controls but not exacerbated in DS.
Huang et al., 1999
Berry et al. 1999 corpus striatum n = 14, 1.2–13.6 years DS
and n-13 1.3–11.7 year old
controls
None MI was significantly higher (28%) in
basal ganglia of DS relative to
controls. Choline containing
compounds were significantly lower in
DS relative to controls.
Berry et al., 1999
Beacher et al. 2005 Hippocampus n = 38, 18–66 years
non-demented DS and n =
42, 19–66 controls
CAMCOG Hippocampal MI was higher in DS
than controls. In DS, hippocampal MI
correlated with cognition.
Beacher et al.,
2005
Smigielska-Kuzia
et al.
2007 Frontal cortex n = 14 non-demented DS
7–17 years, n = 20 controls
None Signficantly decreased Glx and NAA
observed in DS relative to controls.
Smigielska-Kuzia
and Sobaniec,
2007
Smigielska-Kuzia
et al.
2010 Temporal lobes n = 20 DS 3–15 years and
n = 20 controls 6–15 years
None Glx was not different between the DS
and control groups. NAA and MI was
significantly lower in DS relative to
controls. GABA was also lower in DS.
Smigielska-Kuzia
et al., 2010
Lamar et al. 2011 Hippocampus n = 35 demented people
with DS (Avg age = 52.8
years), n = 18
non-demented DS (Avg age
47.2 years) and n = 13
controls (Avg age 50.6
years), n = 39 sporadic AD
(Avg age 76.8 years)
CAMDEX MI was significantly higher in DS with
dementia relative to non-demented
DS (13% higher) and controls (19%
higher).NAA was significantly reduced
in DS with dementia relative to DS
without dementia (11%) but was
similar to controls. DS with dementia
MI was significannlty higher relative to
sporadic AD.
Lamar et al., 2011
Tan et al. 2014 Hippocampus n = 35 non-demented DS
(Avg age 35 years), n = 11
demented DS (Avg age 52
years) and n = 39 controls
(Avg age 35 years)
CAMCOG No differences in Glx across the 3
groups nor correlation with cognition.
Tan et al., 2014
Lin et al. 2016 Posterior
Cingulate Cortex
n = 22 non-demented DS
(Avg age 46.7 years), n = 5
demented DS (Avg age 53.7
years), n = 15 control (Avg
age 47.8 years)
SIB, BPT, DMR NAA reduced in DS with dementia
relative to controls and non-demented
DS groups. MI increased in DS
relative to controls but not further
increased with DS and dementia.
Higher NAA levels associated with
cognition (i.e. better performance
associated with more NAA).
Lin et al., 2016
DMR, dementia questionnaire for mentally retarded persons; BPT, Brief Praxis Test; SIB, severe impairment battery; CAMDEX, Cambridge Mental Disorders of the Elderly Examination;
CAMCOG, Cambridge Cognitive Examination.
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increased neuroinflammation that has been observed with aging
in DS (Wilcock, 2012).
Thus, MRS provides novel information and unique signatures
for DS (e.g., higher MI) but also may be amenable to future
treatment studies as metabolic outcomes measured by MRS
may be rapidly modifiable as opposed to outcomes reflecting
brain structure. Comparing MRS outcomes in different affected
brain regions in people with DS (e.g., comparing hippocampus,
frontal cortex, cingulate cortex) may provide novel links
between the presence of in vivo amyloid by PET imaging
and glial/neuronal consequences. For example, as amyloid PiB
binding increases with age, how does NAA or MI decrease or
increase correspondingly? These studies may lead us to novel
interventions in future for DS with outcome measures and a
further examination of the link between MRS outcomes, brain
region, and cognition will be useful in future.
VASCULAR IMAGING BIOMARKERS
Cerebrovascular pathology occurs in over 85% of autopsy cases
presenting with AD neuropathology and is associated with
impaired cognition (Arvanitakis et al., 2016). One form of this
pathology, cerebral amyloid angiopathy (CAA) is present in near
all brains of people with AD (Viswanathan and Greenberg, 2011).
Thus, there is an increasing recognition that along with the
development of Aβ plaques and neurofibrillary tangles, vascular
neuropathology may also affect cognition and the progression
of dementia (White et al., 2002). Interestingly, in DS, there is
significant cerebrovascular neuropathology in the form of CAA,
primarily due to the overexpression of APP and Aβ (Ikeda et al.,
1994; Iwatsubo et al., 1995; Mendel et al., 2010; Head et al., 2017;
Zis and Strydom, 2018).
Extensive CAA is associated with microhemorrhages and
strokes in general (Arvanitakis et al., 2017; Banerjee et al., 2017)
although in DS, stroke is relatively rare (Buss et al., 2016).
Nonetheless, CAA may have a significant impact on blood vessel
function. CAA can lead to deficits in cerebrovascular regulation
(Grinberg et al., 2012) and reduced blood flow may lead to
impaired perivascular clearance of Aβ. Impaired clearance will in
turn lead to additional accumulation of Aβ (Banerjee et al., 2017).
Neuroimaging of CAA is typically by GRE or T2∗-weighted
MRI (Fazekas et al., 1999). There is only one neuroimaging study
using T2∗ to observe the extent of CAA in vivo in older adults
with DS (Carmona-Iragui et al., 2017). CAA was observed in
31% of cognitively impaired people with DS, which is similar to
early onset AD (38%) and higher than sporadic AD (12%). In
addition, 15.4% of people with DS had evidence of intracerebral
hemorrhages. Thus, CAA is a consistent feature of aging and
dementia in DS and may serve as a future target for clinical trials.
While PET-based studies in DS show metabolic differences
that mirror AD in the general population, changes in blood flow
may also be seen in DS. For example, single photon emission
computed tomography (SPECT) patterns in younger individuals
with DS reveal perfusion changes in temporal, parietal, and
occipital regions (Kao et al., 1993) that are also reminiscent
of those seen in AD (DeKosky et al., 1990). However, these
regional differences in perfusion may reflect the added impact of
CAA-associated or other cerebrovascular mechanisms in DS.
Cerebrovascular dysfunction measured in vivomay be critical
for understanding not only the aging process and progression
to AD in DS but treatment that rely on and are also
relatively short MR protocols (T2∗∼7min, FLAIR∼4.5min)
(Figure 1). Immunotherapy trials in patients with AD suggest
that cerebrovascular adverse effects can occur and are visualized
with FLAIR (Sperling et al., 2012). The possibility of a similar
outcome in DS is as yet unknown. Intervention studies that
target Aβ or other pathways may be less effective in people
with DS with significant cerebrovascular pathology and can
confound the opportunity to observe benefits in clinical trials.
Characterizing the extent of cerebrovascular pathologymay serve
as an exclusion/inclusion criteria or included as a covariate so as
not to obscure positive clinical outcomes.
DEVELOPMENTAL DIFFERENCES AND
CAVEATS WITH NEUROIMAGING IN DS
Structural differences in childhood and early adulthood suggest
that some brain regions (e.g.,) are smaller in people with DS
whereas others (parahippocampal gyrus) may be larger (Kesslak
et al., 1994; Teipel and Hampel, 2006). It will be important
to consider additional volumetric tissue losses using structural
MRI when interpreting reductions in vascular flow or metabolic
outcomes. Additional atrophy occurs with aging in DS and with
the development of dementia with posterior cingulate, parietal,
temporal, and frontal regions being affected (summarized nicely
in Neale et al., 2018).
In studies of people with DS, sample sizes are typically smaller.
This is due to challenges with recruitment, the ability of people
to be scanned (e.g., fear) or to stay motionless (movement
artifacts, people with dementia; Neale et al., 2018). Obesity
or being overweight can lead to discomfort in the scanner
and in some cases, may preclude a person from participating.
The neck and facial structure of people with DS also can
lead to discomfort in the prone position. For these situations,
there are methods to provide additional padding and support
along with frequent pauses in the procedures. Unfortunately,
in many studies this leads to small sample sizes of demented
individuals with DS, which may skew our results. Anxiolytics can
be helpful when obtaining structural images but may interfere
with functional measures. In our own experiences, we have
found that repeated visits leads to greater successes with our
volunteers participating in the scanning procedures and the
option of anxiolytics has been helpful. Age of the participant
also influences success with scanning. Estimates from our cohort
suggest that a full set of images (MPRAGE, FLAIR, T2∗, ASL,
MRS, DTI ∼50min), 92% of people 25–37 years, 82% of 37–50
year olds and 40% of 50–65 year olds can be successfully scanned
(unpublished observations from the University of Kentucky
Down syndrome and Aging study). However, there are fewer sets
of full imaging protocols we can acquire with increasing age as
our participants may not be able to stay in the scanner as long as
we require.
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FIGURE 1 | Representative examples of neuroimaging protocols acquired in Down syndrome. Panels (A–D) show MR imaging in a 57 year old male and 59 year old
male imaged with T2* (A, C) and FLAIR (B, D) showing the presence of microbleeds. Arrows distinguish edema and hemosiderin positive microbleeds. Panel (E)
shows examples of amyloid PiB-PET imaging (top) and FDG-PET imaging (bottom). Images from (A–D) were modified from Figure 5 with permission of Elsevier Press
(Head et al., 2018). Images from (E) were modified from Figure 1 reproduced with permission from Dr. M. Rafii and under the Creative Commons Attribution License
(CC BY) (Rafii et al., 2015).
SUMMARY AND FUTURE DIRECTIONS
Longitudinal studies in virtually all of the imaging parameters
discussed here are critical. There are few longitudinal studies
of metabolic and vascular neuroimaging changes with age in
DS. In studies of structural imaging some show progressive
atrophy (reviewed in Neale et al., 2018). Over a 3 year period
of time, studies in non-demented adults with DS report an
increasing number of individuals developing amyloid by PET
(PiB binding) and those with existing amyloid binding showed an
increasing number of brain regions affected along with increased
accumulation within affected brain regions (Hartley et al., 2017;
Lao et al., 2017; also reviewed in Neale et al., 2018) (Figure 1).
It is interesting to note that PiB tends to bind more mature
amyloid deposits (LeVine et al., 2017) in vitro consistent with
the typical age of onset of PiB binding in DS being after 40
years of age. In summary, neuroimaging is a powerful tool
to detect structural, metabolic and vascular changes with age
and dementia in DS but there are still important gaps in our
knowledge remaining. Feasibility concerns may be overcome
with the use of mock scanners, increasing sample sizes (based
upon estimates of scan success as a function of age and dementia)
and reducing scan times. Given that neuroimaging outcomes
could be critically important in future clinical trials, it will be
important to encourage further studies for people with DS.
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